gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · KYNBHealthcarePharmaceuticals

Kyntra Bio, Inc. Common Stock (KYNB)

$3.96−8.12%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$4.11▼ 56.74% in range
Jan 8, 2026Low $4.11 · High $9.50Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Kyntra Bio closed at $3.96 on Nov 4, down 8.12%, within 0.0% of its lowest close since Jan 8. Volume of 17.6K shares was 0.85× its 20-day average (close to normal).

Split-adjusted performance: -33.6% over one month, -44.4% over six months.

In the quarter ended Jun 30, 2026, revenue was -$1.47M.

Short interest was 95.0K shares at the Oct 15 settlement, down 5.1% from the prior report (2.5% of float, 3.5 days to cover).

Market cap$16.0M4.0M shares
Revenue · quarter-$1.5M—
Diluted EPS$2.96—
P/E · TTM—
Net margin—
Dividend yieldNone
Range since Jan 83.96 – 9.50−58.3% from high
Volume17.6K0.85× 20-day avg
Volatility · 60d57.0%Annualised
Short % of float2.5%3.6 days to cover
Net cash$91.3MCash $91.3M
Next earnings—Not scheduled
Split-adjusted performance
1W −16.1%1M −33.6%3M −43.3%6M −44.4%YTD —1Y —3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum30
Revenue growth—
Net margin—
Value (low P/E)—
Size19

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short95.0K−5.1% vs prior
Days to cover3.6Settled Oct 15
% of float2.5%
Short vol. 10d30.5%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
KYNBKyntra Bio$3.96−8.12%−44.4%———$16.0M
NEUPNeuphoria Therapeutics$2.98−0.33%−44.6%———$16.1MCompare
MTEXMannatech$8.64−0.06%+77.0%+3.8%3.8%—$16.7MCompare
BOLTBolt Biotherapeutics$6.54−0.46%+42.5%−99.7%−154400.0%—$15.4MCompare
MRKRMarker Therapeutics$1.01+2.76%−30.8%———$16.8MCompare
CTXRCitius Pharmaceuticals$0.5510−3.87%−17.3%—−593.3%—$15.1MCompare
ALLRAllarity Therapeutics$1.08−4.42%−27.0%———$17.2MCompare
KTTAPasithea Therapeutics$0.53000.00%−37.6%———$17.7MCompare
CNTXContext Therapeutics$0.2035+4.90%−91.6%———$18.7MCompare

News about Kyntra Bio

All news →
Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of DirectorsGlobeNewswire Inc. · Oct 1, 2026▲ PositiveKyntra Bio to Report Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire Inc. · Mar 9, 2026Neutral

Quick answers

What does Kyntra Bio do?
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC).
What is KYNB's market cap?
$16.03M, based on the Nov 4 close of $3.96.
Does Kyntra Bio pay a dividend?
No regular cash dividend has been paid in the last year.
How much of KYNB is sold short?
95.0K shares, 2.5% of float, as of Oct 15, 2026.
What sector is KYNB in?
Healthcare, in the Pharmaceuticals industry.

About Kyntra Bio

Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.

HQ: San Francisco, CA34 employeesListed Nov 14, 2014kyntrabio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology